The study is testing the new medicine NNC0662-0419 in people living with overweight or obesity. The purpose of the study is to look into the amount of the new medicine NNC0662-0419 in participants blood after one dose. And also look into how safe and how well the study medicine is tolerated in people living with overweight or obesity. NNC0662-0419 is a new medicine which cannot be prescribed by doctors. NNC0662-0419 is currently being tested in humans and the dose participants will receive has been found safe and tolerable. Participants will get a single dose of NNC0662-0419 given by study staff as a single injection under participants skin. Like all medicines, the study medicine may have side effects. The study will last up to 2 months.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
100
Participants will receive NNC0662-0419 subcutaneously.
Altasciences Clinical LA, Inc.
Cypress, California, United States
AUC; The area under the NNC0662-0419 plasma concentration-time curve
Measured in hours\*nanomoles per liter (h\*nmol/L).
Time frame: From pre-dose on Day 1 until completion of the end of study visit (Day 29)
Cmax; The maximum plasma concentration of NNC0662-0419
Measured in nanomoles per liter (nmol/L).
Time frame: From pre-dose on Day 1 until completion of the end of study visit (Day 29)
Number of treatment-emergent adverse events (TEAEs)
Measured as number of events.
Time frame: From time of dosing on Day 1 until completion of the end of study visit (Day 29)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.